MedTrace Logo

Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective.

NCT03119805 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 466

Last updated 2018-10-17

No results posted yet for this study

Summary

The purpose of this study is to define cut-off values of the most widely used composite scores and patient-reported outcomes, for levels corresponding to remission/low disease activity and for changes in levels corresponding to flares, in PsA, when remission/low disease activity and flare are defined from the patient and physician perspective. The ReFlaP (Remission/Flare in PsA) study is a prospective, multicentric international, longitudinal, observational study.

Conditions

Sponsors & Collaborators

  • Groupe Hospitalier Pitie-Salpetriere

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-18
Primary Completion
2018-01-30
Completion
2018-07-30

Countries

  • United States
  • Austria
  • Brazil
  • Canada
  • Estonia
  • France
  • Germany
  • Italy
  • Romania
  • Russia
  • Singapore
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03119805 on ClinicalTrials.gov